Not a cardiologist but Praluent has the following indication in the USA:
PRALUENT is...indicated as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-cholesterol (LDL-C).
Oddly, no mention of HoFH. But both are approved for ASCVD.
It's up to the company, Amgen, to make the announcement, not the FDA. Amgen will do whatever seems most appropriate to them. All companies handle things their own way and those ways can vary over time.
"If I could predict what stocks will do, well then I would not be on this board."
I'll try to keep that in mind with any future predictions. Happy investing!
It all assumes that Regeneron executes their rollout effectively. Remember how Immunex botched their rollout of Enbrel? That's why they came to be acquired by Amgen. Also, it allowed Humira to be approved sooner and grow faster. Not saying that that's what will happen but if REGN is slow on the output and AMGN is a model of efficiency, the month may not make any difference.
R&D has an exemption from patent infringement. That includes clinical trials. A company is only infringing if they are selling another company's patent protected item while the patent is still in force. No money is made during development.
Go back to learning about stock splits. And, no, stock splits do not dilute a stock because the overall equity on the balance sheet doesn't change. LOL
You jinxed it by posting that you that you thought that the share price should be $160 soon. Karma pay back!
Amgen is not going to be making generics of their own stuff, they will be making generics of other companies' stuff. Think Humira, Rituxan, Herceptin.
To summarize, the share exchange in an inversion will be taxed as capital gains. If the company's executives and directors have tax, the company will probably pay the tax for the poor babies.
AbbVie will probably pay for any taxes incurred by their executives and board. So in essence, the other shareholders will pay.